Sarepta Therapeutics, Inc. (SRPT)
23.21
+1.88
(+8.81%)
USD |
NASDAQ |
Sep 02, 16:00
23.04
-0.17
(-0.73%)
After-Hours: 06:51
Sarepta Therapeutics Research and Development Expense (TTM) : 783.60M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 783.60M |
| March 31, 2026 | 896.74M |
| December 31, 2025 | 1.516B |
| September 30, 2025 | 1.389B |
| June 30, 2025 | 1.388B |
| March 31, 2025 | 1.358B |
| December 31, 2024 | 778.47M |
| September 30, 2024 | 773.18M |
| June 30, 2024 | 741.55M |
| March 31, 2024 | 801.60M |
| December 31, 2023 | 844.38M |
| September 30, 2023 | 862.87M |
| June 30, 2023 | 885.22M |
| March 31, 2023 | 896.28M |
| December 31, 2022 | 845.38M |
| September 30, 2022 | 829.63M |
| June 30, 2022 | 752.76M |
| March 31, 2022 | 741.51M |
| December 31, 2021 | 743.89M |
| September 30, 2021 | 755.82M |
| June 30, 2021 | 810.07M |
| March 31, 2021 | 760.83M |
| December 31, 2020 | 704.19M |
| September 30, 2020 | 725.15M |
| June 30, 2020 | 673.18M |
| Date | Value |
|---|---|
| March 31, 2020 | 602.12M |
| December 31, 2019 | 560.71M |
| September 30, 2019 | 480.18M |
| June 30, 2019 | 432.81M |
| March 31, 2019 | 442.39M |
| December 31, 2018 | 398.04M |
| September 30, 2018 | 300.07M |
| June 30, 2018 | 247.72M |
| March 31, 2018 | 183.78M |
| December 31, 2017 | 166.62M |
| September 30, 2017 | 192.94M |
| June 30, 2017 | 192.28M |
| March 31, 2017 | 177.21M |
| December 31, 2016 | 186.49M |
| September 30, 2016 | 157.12M |
| June 30, 2016 | 160.21M |
| March 31, 2016 | 145.55M |
| December 31, 2015 | 146.39M |
| September 30, 2015 | 135.85M |
| June 30, 2015 | 121.03M |
| March 31, 2015 | 112.49M |
| December 31, 2014 | 94.23M |
| September 30, 2014 | 88.48M |
| June 30, 2014 | 87.66M |
| March 31, 2014 | 80.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Moderna, Inc. | 2.635B |
| Arrowhead Pharmaceuticals, Inc. | 699.56M |
| ImmunityBio, Inc. | 241.79M |
| X4 Pharmaceuticals, Inc. | 66.27M |
| MapLight Therapeutics, Inc. | 198.70M |